Rituximab biosimilar, chimeric monoclonal antibody which specifically binds to the transmembrane antigen CD20. Indications: non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Currently > 150 000 patients treated, > 2 100 000 vials sold, marketed in 26 countries.

*Numbers of vials/patients treated relevant as of January 2022. The calculation of patients is based on the average recommended doses, average patient weight, and the approximate duration of therapy